Live Attenuated Vaccines Market Trends Are Creating New Opportunities For Industry Leaders
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Live Attenuated Vaccines Market Forecast: What Market Value Is Expected By 2030?
The market for live attenuated vaccines has experienced robust expansion over the past few years. Valued at $25.95 billion in 2025, it is projected to reach $28.52 billion by 2026, reflecting a compound annual growth rate of 9.9%. This historical growth can be linked to the worldwide impact of infectious diseases, governmental vaccination campaigns, policies mandating childhood immunization, vaccine administration within hospital settings, and vaccination initiatives spearheaded by the World Health Organization.
The market for live attenuated vaccines is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $41.11 billion, driven by a compound annual growth rate (CAGR) of 9.6%. This forecasted growth is fueled by factors such as the rising need for booster shots, the threat posed by new infectious diseases, improvements in cold chain logistics, enhanced global health investments, and the emergence of next-generation vaccine platforms. Key developments shaping this period include the broadening of national vaccination initiatives, increasing requirements for childhood immunizations, betterments in vaccine stability and preservation, a heightened emphasis on pandemic readiness, and the creation of multivalent vaccines.
Download A Free Sample Report For Comprehensive Market Insights:
Live Attenuated Vaccines Market Development Factors: Which Trends Are Supporting Demand?
The rising occurrence of infectious diseases is anticipated to boost the expansion of the live attenuated vaccines market going forward. Infectious diseases refer to conditions caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between people, animals, or environments. The growth of international travel facilitates the swift spread of these illnesses, enabling pathogens to cross borders more rapidly than containment efforts can respond. Live attenuated vaccines are used to prevent infectious diseases by eliciting a strong immune response through weakened pathogens, providing durable immunity and curbing disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental body headquartered in Switzerland, reported that an estimated 10.8 million individuals contracted tuberculosis globally in 2023, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the heightened prevalence of infectious diseases is fueling the growth of the live attenuated vaccines market.
Live Attenuated Vaccines Market Segment Breakdown: Which Categories Generate The Most Revenue?
The live attenuated vaccines market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated
3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users
Subsegments:
1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines
2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines
Live Attenuated Vaccines Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the live attenuated vaccines market are placing significant emphasis on the creation of advanced solutions, particularly single-dose vaccines, to boost immunization effectiveness and increase patient adherence. A single-dose formulation offers lifelong protection through just one injection, removing the necessity for repeated administrations. This approach makes vaccination more straightforward for both individuals and medical professionals, thereby improving ease of use and overall reach. A noteworthy example is Valneva SE, a biotech firm headquartered in France specializing in infectious disease vaccines, which introduced IXCHIQ in November 2023. This product secured approval from the U.S. Food and Drug Administration (FDA), an American health regulatory authority. IXCHIQ represents the first live-attenuated chikungunya vaccine globally, designed for individuals aged 18 and above. This regulatory milestone holds considerable importance as it marks the debut of a licensed vaccine for chikungunya, filling a critical gap in preventive care for this mosquito-borne viral illness, which is known to trigger intense fever, joint and muscle discomfort, along with other adverse effects.
Live Attenuated Vaccines Market Key Players And Strategic Industry Positioning
Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals
Access The Complete Live Attenuated Vaccines Market Report:
Live Attenuated Vaccines Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
